U.S. stocks closed another record-setting week with a muted performance Friday, as hope built on Wall Street that the U.S. economy can manage the rare feat of suppressing high inflation without ...
The Dow Jones Industrial Average edged up to another record high while declines in tech stocks pulled other indexes lower.
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
In a breakthrough for people with schizophrenia, the FDA has approved a new oral medication for adults. Unlike traditional antipsychotic drugs, the medication, which will be marketed under the name ...
Bristol Myers trades higher after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter ...
British scientists have hailed the US approval of a new drug for schizophrenia, saying it “has the potential to change the ...
U.S. stock indexes are drifting around their records Friday as hopes hold that the economy can pull off the rare feat of ...
Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in decades.
Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.
By way of two resoundingly consistent votes, members of an FDA advisory committee agreed that PD-1 inhibitors do not have a favorable risk/benefit profile for gastroesophageal cancers with low PD-L1 ...
The FDA approval of Bristol Myers Squibb's Cobenfy for schizophrenia could revolutionize treatment, but faces a competitive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback